PRNewsWire · October 25, 2026

Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO

Get the app for more

Explore stock news, insights and company research.